Medicine
Kisunla 350 mg/20 mL injection
Kisunla 350 mg/20 mL injection is a prescription medicine containing Donanemab for intravenous use, marketed by Eli Lilly, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. If…
Key facts
- Active ingredient (INN)
- Donanemab
- Brand
- Kisunla
- Strength
- 350 mg/20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 20 mL
- Marketing authorisation holder
- Eli Lilly
- Manufacturer
- Eli Lilly
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. If refrigeration is not available, may be stored at room temperature (20°C to 25°C [68°F to 77°F]) for up to 3 days. Keep the vial in the outer carton to protect from light. Diluted Solution For storage of the diluted infusion solution see Dosage and Administration.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06DX05 Donanemab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 July 2024
- Identifiers
- RxCUI 2687972, 2687979DailyMed set ID 190352d4-ef62-4679-b4fa-e846e2766afaNDC 0002-9401Application BLA761248
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 0002-9401-01 | Eli Lilly | 2 July 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Donanemab is a prescription medicine indicated for the treatment of Alzheimer's disease. It is available as injection for intravenous use. MedsAcross supplies Donanemab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DonanemabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Kisunla prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Kisunla: European public assessment report (EPAR) · European Medicines Agency
Need Kisunla 350 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.